Tele-Epilepsy Market to Surge to $1,468.32 Million by 2032, Driven by 15.98% CAGR, Revolutionizing Epilepsy Care

January 21, 2025 02:49 AM PST | By EIN Presswire
 Tele-Epilepsy Market to Surge to $1,468.32 Million by 2032, Driven by 15.98% CAGR, Revolutionizing Epilepsy Care
Image source: EIN Presswire

Innovative Telemedicine Solutions Propel Market Growth with AI-Enhanced Seizure Management and Personalized Remote Care AUSTIN, TX, UNITED STATES, January 21, 2025 /EINPresswire.com/ -- According to Research by SNS Insider, The Tele-Epilepsy Market was estimated at USD 387.43 million in 2023 and is expected to reach USD 1468.32 million by 2032, at a CAGR of 15.98% during the forecast period of 2024-2032.

Tele-epilepsy Market Growth Driven by Personalized Solutions, Regional Expansion, and Cutting-Edge Innovations, Revolutionizing Epilepsy Care

The tele-epilepsy market is witnessing notable expansion, driven by advancements in telemedicine, the growing incidence of epilepsy, and the rising need for remote healthcare services. Utilizing technologies like wearable EEG gadgets, mobile apps, and teleconsultations, tele-epilepsy allows for ongoing monitoring and individualized care, supporting prompt interventions and customized treatment strategies. The combination of AI and machine learning boosts the accuracy of seizure prediction and treatment, increasing trustworthiness for both patients and healthcare providers. Tele-epilepsy is especially advantageous for all age groups, providing essential assistance to children via early intervention and to adults in need of adaptable care solutions, particularly in rural locations. With healthcare providers embracing these solutions and developing markets to enhance their infrastructure, tele-epilepsy is set to transform epilepsy management and greatly enhance patient outcomes worldwide.

Get a Free Sample Report of Tele-Epilepsy Market @ https://www.snsinsider.com/sample-request/4945

Key Players in Tele-Epilepsy Market
• Daicel Arbor Biosciences (myBaits Target Capture Kits, myTXTL Cell-Free Protein Expression System)
• Thermo Fisher Scientific (Ion Torrent Genexus System, Invitrogen QuantiGene Plex Assay)
• NeuroPace, Inc. (RNS System, NeuroPace Monitoring System)
• Cerner Corporation (Cerner Telemedicine Services, Cerner Epilepsy Management Software)
• Livongo Health (now part of Teladoc Health) (Livongo for Epilepsy, Livongo Telehealth Platform)
• Medtronic (Medtronic's Remote Monitoring Epilepsy Management System, Neurostimulators for Epilepsy Treatment)
• MedeAnalytics (MedeAnalytics Telehealth Data Analytics, Epilepsy Monitoring and Management Solutions)
• MyEpilepsyHome (by UCB) (MyEpilepsyHome, Seizure Tracker)
• Epitel (Epitel Epilepsy Monitoring System, Epitel Seizure Detection Platform)
• Embrace by Empatica (Embrace2 Seizure Detection Smartwatch, Embrace Seizure Alert Device)
• Neuromotion (Neurostimulator for Epilepsy Management, Neuromotion Epilepsy Remote Monitoring)
• Brain Sentinel (Brain Sentinel Epilepsy Monitoring System, Brain Sentinel Seizure Detection Wearable)
• NeuroSigma (Monarch eTNS System, NeuroSigma Epilepsy Monitoring Solutions)
• LivaNova (Vagus Nerve Stimulation for Epilepsy, Epilepsy Remote Monitoring Services)
• BioSerenity (BioSerenity Epilepsy Monitoring Kit, BioSerenity Data-Driven Epilepsy Management Platform)
• UCB Pharma (Vimpat, MyEpilepsyHome)
• MedPage Today (Telemedicine Solutions for Epilepsy Management, Virtual Epilepsy Consultations)
• ZygoCare (ZygoCare Tele-epilepsy Management Platform, Remote Epilepsy Monitoring Solution)
• Epilepsy Foundation (Epilepsy Telehealth Resource Center, Epilepsy Telemedicine Toolkit)
• BenevolentAI (AI-based Epilepsy Treatment Platform, Epilepsy Data Analytics for Remote Care Solutions)

Segment Analysis
By Patient
The Adult segment dominated the tele-epilepsy market in 2023, capturing a 54% market share. This increase is fueled by the significant rate of epilepsy in adults, as 2.9 million adults in the U.S. have reported active epilepsy, according to the CDC. Technological progress facilitating immediate oversight and tailored care additionally boosts the growth of the segment.

The Pediatric segment is expected to expand at the fastest growth, driven by the increasing occurrence of epilepsy among children and the demand for tailored treatment. Disorders such as Lennox-Gastaut syndrome and childhood absence epilepsy emphasize the specific needs of pediatric patients. The 2022 National Survey of Children's Health indicated that 456,149 children in the U.S. are affected by active epilepsy, highlighting the opportunity for customized tele-epilepsy solutions for this group.

End-use
The Healthcare Consumer segment dominated the tele-epilepsy market in 2023, representing 53% of the market share. This increase arises from the growing need for personalized, accessible healthcare options and the uptake of wearable devices and mobile applications that enable patients to track seizures and obtain immediate feedback. Raising public awareness of telehealth services further fuels the growth of the segment.

The Hospital Providers segment is expected to achieve the fastest CAGR throughout the forecast duration. Hospitals continue to be the favored option for care because of their availability and extensive offerings. As of January 2023, there were about 7,335 operational hospitals in the U.S., indicating consistent expansion in healthcare facilities. The availability and variety of care choices greatly enhance the swift growth of this segment.

Need any customization research on Tele-Epilepsy Market, Enquire Now @ https://www.snsinsider.com/enquiry/4945

Tele-Epilepsy Market Segmentation
By Patient
• Pediatric
• Adult

By Component
• Software
• Hardware
• Services

By End Use
• Hospitals providers
• Payers
• Healthcare consumers

Regional Analysis: North America and Asia Pacific
In 2023, North America dominated the tele-epilepsy market, accounting for a 37% market share. This leadership is linked to improved technological infrastructure, a growing prevalence of epilepsy, and higher per capita income. The existence of major market participants and favorable government regulations enhance regional development.

The Asia Pacific region is anticipated to achieve the fastest CAGR throughout the forecast period, fueled by the extensive use of smartphones and smart wearables, as well as the increasing acceptance of telehealth services. Rising demand for remote patient monitoring, bolstered by substantial government funding in healthcare, is expected to drive market growth in this area.

Recent Developments
• In June 2024, Daicel Arbor Biosciences launched an updated version of their myTXTL kits, optimized for cell-free protein production. These kits support the development of therapeutic proteins, including those targeting epilepsy treatment. This innovation is expected to indirectly contribute to advancements in epilepsy care by facilitating research into therapeutic protein solutions.
• In October 2023, Thermo Fisher Scientific acquired Olink Holding for USD 3.1 billion, expanding its expertise in proteomics. Although not directly linked to tele-epilepsy, this acquisition could drive innovations in molecular diagnostics, potentially enhancing tele-epilepsy monitoring systems and improving patient care.

Buy Full Research Report on Tele-Epilepsy Market 2024-2032 @ https://www.snsinsider.com/checkout/4945

Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
6. Competitive Landscape
7. Tele-Epilepsy Market by Patient
8. Tele-Epilepsy Market by Component
9. Tele-Epilepsy Market by End Use
10. Regional Analysis
11. Company Profiles
12. Use Cases and Best Practices
13. Conclusion

Speak with Our Expert Analyst Today to Gain Deeper Insights @ https://www.snsinsider.com/request-analyst/4945

About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

Browse More Insights:
Epilepsy Device Market Size, Share & Growth Report
Epilepsy Drugs Market Size, Share & Growth Report

Akash Anand
SNS Insider Pvt. Ltd
415-230-0044
email us here
Visit us on social media:
Facebook
X
LinkedIn
Instagram

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


Investing Ideas

Previous Next